Volcano's CEO sees $2B market for heart stent Dx; Analogic forks over $83M for Canadian ultrasound maker;

 @FierceMedDev: Samsung med device sales spike in 2012. Item | Follow @FierceMedDev

@MarkHFierce: Abbott is beginning a bioresorbable stent trial in the U.S. Big news for the company and its stent rivals alike. More | Follow @MarkHFierce

 @DamianFierce: $LIFE is teaming up with Boston Children's Hospital to develop genomics-based diagnostics. News | Follow @DamianFierce

> Volcano CEO Scott Huennekens ($VOLC) said during the J.P. Morgan Healthcare Conference in San Francisco that the company's diagnostic to spot patients who need heart stents could lead to a $2 billion market over the next 10 years. Story

> Analogic ($ALOG) will buy Canadian ultrasound system maker Ultrasonix Medical for $83 million. Story

> Jerusalem device company Brainsway has seen its stock soar, following FDA approval for its device to address depression when drug treatments fail to work, Bloomberg reports. Story

> Amedica, a spine and orthopedic implant and devicemaker, obtained a $231.5 million senior secured credit facility from GE Capital. The new funding will support the Maryland company's expansion. Item

> Riverain Technologies won FDA 510(k) clearance for new software designed to make conventional chest X-rays clearer and help radiologists rapidly confirm placement of tubes, lines and wires. Release

> Canada's Sernova is pursuing a diabetes treatment that combines an implanted device with a cell therapy. Story

Biotech News

 @FierceBiotech: Buyout buzz: Biopharma players staying focused on bolt-on deals. Report | Follow @FierceBiotech

@JohnCFierce: Medicines Co. spikes after anti-clotting drug impresses in second run at PhIII. Story | Follow @JohnCFierce

> Baxter preps BLA on successful end to PhIII hemophilia drug study. More

> Payer risk outrivals regulatory jitters as biggest biotech hurdle. News

Pharma News

@FiercePharma: Will Bausch + Lomb choose IPO over a sale to pharma? Related Q: Can Warburg Pincus get its $10B+ asking price? More | Follow @FiercePharma

@EricPFierce: COO Perez says Cubist well positioned in new hospital-centric payer world. "The world has turned and we are Cinderella now." | Follow @EricPFierce

 @AlisonBFierce: Altravax landed $1.2M from NIAID to advance its dengue vaccine and hepatitis therapeutic. More | Follow @AlisonBFierce

> AbbVie CFO sees no need for big acquisition. Report

> Swiss insurer jumps into legal fight over Bayer's Yasmin. News

> Teva CEO says job cuts are small part of efficiency plans. Story

Drug Delivery News

> Alnylam prepares for U.K. Phase I and plans for the future. Article

> Agile snags $15M loan to push pipeline products forward. News

> FDA approves EMD Serono-Pfizer's Rebif auto-injector. Item

> FDA grants orphan label to eye cancer chemo-delivery combo. Story

Biomarkers News

> Biomarkers could tag chemo heart risk. Item

> Stem cell factor could improve ovarian cancer prognosis. Article

> Crescendo Bioscience deploys $28M Series D to market RA Dx biomarker test. News

> New target could improve treatment of deadly pancreatic cancer. Story